What is the Origin of Postmenopausal Testosterone Therapy?

This practice evolved from the recognition in endocrinology that the ovaries and adrenal glands continue to produce androgens after menopause, and that a significant decline in testosterone can contribute to a decline in quality of life. The therapy has been a subject of extensive clinical research and regulatory discussion, seeking to establish appropriate indications and long-term safety profiles in women. It is a nuanced aspect of hormone replacement therapy.

What is the Mechanism of Postmenopausal Testosterone Therapy?

Exogenous testosterone binds to the androgen receptor (AR) in target tissues, exerting genomic and non-genomic effects that influence muscle, bone, and brain function. In adipose tissue, it can promote lipolysis, and in the brain, it acts as a neurosteroid to influence libido and cognitive function. The administered testosterone is often converted peripherally to dihydrotestosterone (DHT) and, to a lesser extent, to estrogen via the aromatase enzyme, contributing to its systemic effects.

Postmenopausal Testosterone Therapy ∞ Area

Postmenopausal Testosterone Therapy

Meaning

Postmenopausal testosterone therapy is the clinical administration of exogenous testosterone to women who have completed menopause, with the primary therapeutic goal of alleviating symptoms associated with clinically diagnosed androgen deficiency. This targeted intervention is typically used to address hypoactive sexual desire disorder, improve bone mineral density, and enhance energy levels and mood in appropriately selected patients. The treatment requires careful, individualized dose management and regular monitoring of serum testosterone and free testosterone levels to ensure safety and efficacy.